Ratings CureVac N.V. Deutsche Boerse AG

Equities

5CV

NL0015436031

Real-time Estimate Tradegate Other stock markets 07:36:30 2024-06-10 EDT			5-day change	1st Jan Change
4.21 ^EUR	+1.30%		+5.55%	+9.90%

05-28	CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	MT
05-28	CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CUREVAC N.V.	+9.90%	1.01B	-
MODERNA, INC.	+51.85%	57.87B	B-
LONZA GROUP AG	+41.53%	40.25B	A
IQVIA HOLDINGS INC.	-5.25%	39.94B	B
CELLTRION, INC.	-5.16%	28.54B	C
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B	B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B	C+
BIO-TECHNE CORPORATION	+0.61%	12.23B	B+
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes